



CHALCONES AS INOS AND COX-2 INHIBITORS; INSIGHTS FROM MOLECULAR DOCKING STUDIES

Shaheen begum^{a,*}, K. Bharathi^a, A. Mallika^b

^{a,*} Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Technology, Sri Padmavati Mahila Visvavidyalayam (Women's University), Tirupati 517502, Andhra Pradesh, India.

^b Lecturer, Department of Medicinal chemistry, National Institute of Pharmaceutical Education and Research - Hyderabad, Balanagar, Hyderabad.

*Corresponding Author Email: shaheen.pharmchem@gmail.com

ABSTRACT

In the present study, a series of ring substituted chalcones were docked into the binding sites of COX-2 and iNOS enzymes. These enzymes exhibit similarities in terms of pathophysiological activities and are mostly co-expressed in cancer tissues. Dual inhibition of these enzymes has been proposed as a promising therapeutic tool in the treatment of various types of diseases, especially for antiinflammatory and antinociceptive drug development. Results of docking experiments revealed that these structurally simple molecules have good binding affinity for the enzymes and electronic effects have profound influence on the binding interactions. Trifluoro methyl substituted chalcone, (C12) was found to have highest binding affinity among the chalcones studied, indicating the importance of strong electron withdrawing effect at this position. Predicted molecular properties of these compounds demonstrated good oral bioavailability and CNS permeability.

KEY WORDS

Chalcones; COX-2; iNOS; Molecular docking; Schrödinger

INTRODUCTION

Chalcones (1,3-diaryl-2-propen-1-one) are the most familiar molecules among natural as well as synthetic chemists for their diverse set of biological and enzyme inhibitory activities [1,2]. The compounds with the backbone of chalcone structure have been reported to possess various biological activities such as anti-cancer [3-4], antifungal [5], antileishmanial [6], antiinflammatory [7], antimalarial [8], antiplatelet [9], antihyperglycemic [10], antitubercular [11], antiviral [12] and antimicrobial activities [13]. Chalcones and their derivatives have gained high interest due to their antioxidant properties [14-16]. Antinociceptive activities of chalcones were also reported in the literature [17-19]. The α,β -unsaturated ketone group in chalcone is responsible for their enzyme inhibitory activity including xanthine oxidase, aldose reductase, soluble epoxide hydrolase, protein tyrosine kinase, quinone reductase and mono amine oxidase [13].

Compounds containing this type of unsaturated system are considered as potential drug candidates due to their ability to act as Michael acceptors with the protein functional groups, especially the sulfhydryl group of cysteines in proteins plays a major role in Michael-addition-based activation process [20-21]. Despite their simple substitution patterns, chalcones exert antinociceptive actions in different models of pain and were more potent than some of the well-known anti inflammatory and analgesic drugs [22-24]. Chalcones possessing aryl or hetero aryl ring demonstrated significant in vitro inhibition of inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2) enzymes. Presence of halogens, electron releasing groups such as hydroxy, alkoxy groups and side chains such as prenyl, geranyl and dimethylamino groups were found to enhance the in vitro inhibitory activity of chalcones [25-27]. Dual inhibition of these enzymes appears as a promising therapeutic tool in the treatment of various types of diseases, especially

for antiinflammatory and antinociceptive drug development [28-30].

In view of the potent in vitro iNOS and COX-2 inhibitory activities of the chalcones, we performed docking studies to analyse in silico binding affinity of these ligands against these enzymes. Chalcones bearing various electron withdrawing and donating groups present on ring A were selected, to analyse their binding poses in the respective enzyme active pockets.

MATERIALS AND METHODS

Protein preparation: Crystal co-ordinates of proteins were downloaded (PDB ID: 2Y37 for iNOS and 3LY1 for COX-2) from the Protein Databank (PDB) (<http://www.pdb.org/>). They were imported into the Schrödinger Maestro suite 2013 (Schrödinger, LLC, New York, NY, 2013) for preparation, minimization and docking studies. Proteins were prepared for docking using protein prep wizard of Schrödinger. Hydrogen atoms, charges were added to protein structure and missing amino acids were taken care by using Prime module of Schrödinger. Finally, grid co-ordinates were calculated based upon the co-crystal ligands in PDB. Grid co-ordinates were set to X: 20.78; Y: -68.94; Z: 32.87 for iNOS and X: 30.67, Y: -22.53, Z: -16.06 for COX-2 to generate the grid box. Glide SP docking was used to carry out docking calculations.

Ligand preparation: A series of ring substituted chalcones were selected as ligands for docking studies. Molecular docking study of these chalcones has been carried out using Glide, module of Schrödinger suite 2013. Ligand molecules were sketched and optimized using LIGPREP wizard and 10 conformations were generated for each compound.

Prediction of Molecular and ADME descriptors: Molecular descriptors, such as log P (partition coefficient), molecular weight (MW), the acceptors and donors for hydrogen bonding in a molecule and polar surface area (PSA) were calculated using the online software (<http://www.molinspiration.com/>).

These descriptors are strongly associated with membrane permeability and oral bioavailability (The "Lipinski rule" states that the compounds are more likely to be orally bioavailable if they obey the rule and fulfil following criteria: $\log p \leq 5$, molecular weight ≤ 500 , hydrogen bond acceptors ≤ 10 , and hydrogen bond donors ≤ 5). The percentage of absorption was estimated using the equation: $\% \text{ ABS} = 109 - (0.345 \times \text{TPSA})$ [31]. Absorption, distribution, metabolism and excretion (ADME) properties of molecules were predicted using the preADMET online server (<http://preadmet.bmdrc.org/>). This program calculates the human intestinal absorption, in vitro Caco-2 cell permeability, Maden Darby Canine Kidney (MDCK) cell permeability, skin permeability, plasma protein binding, blood brain barrier penetration, and carcinogenicity. The blood brain barrier permeability was also estimated using Log BB value, which can be calculated using PSA value with the clark equation $\text{Log BB} = (-) 0.0148\text{PSA} + 0.152 \text{Log P} + 0.139$ [32].

RESULTS AND DISCUSSION

Molecular docking studies using iNOS enzyme:

To determine the importance of various steric, polar and electronic effects of substituent groups at the active sites of COX-2 and iNOS, a series of ring substituted chalcone derivatives (Fig.1) were selected for docking studies. Met368, Glu371 and Asp376 were the critical amino acids of iNOS, having key interactions with standard inhibitor 2Y37_A54, 2-[(1R)-3-amino-1-phenylpropoxyl]-4-chlorobenzonitrile and the glide score for this inhibitor was found to be -8.68 kJ mol⁻¹. Within the amino acids surrounding the active site of iNOS, NH proton of Met 368 form strong hydrogen bonding with triply bonded nitrogen of benzonitrile group present in standard inhibitor. Amino functionality linked to phenylpropoxy group of standard compound, found to participate in important hydrogen bonding interactions with amino acid residues Asn 376 and Glu 371.




Figure 1: Binding conformation of standard inhibitor (A) and compound 12 (B) within the active site of iNOS:




Figure 2: Best docking poses of standard inhibitor (A) and chalcones C2,C5 and C12 (B,C and D) as obtained using GLIDE at COX-2 enzyme

Binding free energies obtained for chalcones with respect to iNOS (Table.1) suggest that unsubstituted chalcone has significant binding affinity for this enzyme ($-7.39 \text{ kJ mol}^{-1}$), indicating that chalcone motif has essential features to bind with iNOS enzyme. Introduction of halogens increased the binding affinity

for this enzyme. Highest docking score was observed with halogen containing trifluoro methyl substituted chalcone (C12), which is $-7.847 \text{ kJ mol}^{-1}$ comparable to standard inhibitor - 8.68 kJ mol^{-1} , implying that halogens enhance binding ability of chalcone towards this enzyme.

Table 1: Interaction energies of ring substituted chalcones (C1- C12) with iNOS and COX-2 enzymes using GLIDE

Compd.	R	Interaction Energy (kJ mol ⁻¹) for iNOS	Interaction Energy (kJ mol ⁻¹) for COX-2
Standard		-8.68	-11.875
C1	H	-7.391	-8.644
C2	4-F	-7.526	-8.875
C3	4-Cl	-7.329	-8.989
C4	2,5-(Cl) ₂	-7.364	-8.753
C5	4-NO ₂	-6.746	-9.096
C6	4-OH	-5.722	-8.970
C7	4-OCH ₃	-6.455	-8.000
C8	3,4-(OCH ₃) ₂	-6.615	-8.696
C9	3,4,5-(OCH ₃) ₃	-7.082	-8.783
C10	4-CH ₃	-6.827	-8.423
C11	4-C(CH ₃) ₃	-7.521	-8.121
C12	CF ₃	-7.847	-9.259

Table 2: Calculated ADME descriptors for the chalcones (C1-C12)

Compd	R	Absorption	Distribution		
		Caco-2 cell (nm sec ⁻¹)	%HIA	PPB (%)	BBB
C1	H	54.59	100.00	94.83	1.51
C2	4-F	57.75	100.00	96.64	1.42
C3	4-Cl	56.98	100.00	100.00	2.97
C4	2,5-(Cl)₂	56.65	100.00	100.00	2.33
C5	4-NO₂	22.35	98.608	93.35	0.01
C6	4-OH	53.54	96.035	91.87	1.15
C7	4-OCH₃	57.99	100.00	91.40	0.34
C8	3,4-(OCH₃)₂	57.45	98.073	90.21	0.09
C9	3,4,5-(OCH₃)₃	54.55	97.64	90.69	0.09
C10	4-CH₃	54.59	100.00	93.16	3.36
C11	4-C(CH₃)₃	54.98	100.00	95.90	8.21
C12	CF₃	40.44	100.00	94.57	5.49

CaCO₂ (nm/sec), CaCO₂ cell permeability in nm/sec; HI A (%), Percentage human intestinal absorption; PPB (%), *in vitro* plasma protein binding (percentage); BBB (C brain/C blood), *in vivo* Blood-Brain Barrier penetration.

Table 3: Calculated theoretical molecular descriptors for the chalcones (C1 - C12)

Compd	R	miLog P	PSA	MW	HBA	HBD	LogBB	nrotb	%ABS	MV
C1	H	3.81	17.07	208.26	1	0	0.466	3	103.11	201.85
C2	4-F	3.98	17.07	226.25	1	0	0.491	3	103.11	206.78
C3	4-Cl	4.49	17.07	242.71	1	0	0.569	3	103.11	215.39
C4	2,5-(Cl) ₂	4.92	17.07	277.15	1	0	0.634	3	103.11	228.92
C5	4-NO ₂	3.77	62.90	253.26	4	0	-0.070	4	87.29	225.19
C6	4-OH	3.33	37.30	224.26	2	1	0.093	3	96.13	209.87
C7	4-OCH ₃	3.87	26.30	238.29	2	0	0.338	4	99.92	227.40
C8	3,4-(OCH ₃) ₂	3.46	35.54	268.31	3	0	0.139	5	96.73	252.94
C9	3,4,5-(OCH ₃) ₃	3.44	44.77	298.34	4	0	0.142	6	93.56	278.49
C10	4-CH ₃	4.26	17.07	222.29	1	0	0.534	3	103.11	218.41
C11	4-C(CH ₃) ₃	5.52	17.07	264.37	1	0	0.726	4	103.11	268.04
C12	CF ₃	4.71	17.07	276.26	1	0	0.602	4	103.11	233.15

miLogP: Logarithm of partition coefficient between n-octanol and water PSA: polar surface area; MW: molecular weight; HBA: Hydrogen bond acceptors; HBD: Hydrogen bond donors; nrotb: Number of rotatable bonds; % ABS: Absorption; MV: Molecular volume ; Log BB: Blood brain barrier permeability.

Presence of strong electron withdrawing group, -NO₂ decreases the affinity of chalcones for iNOS (-6.746 kJ mol⁻¹) when compared to unsubstituted chalcone (-7.39 kJ mol⁻¹) indicating that factors other than electron withdrawing effects may be responsible for high affinity at this position.

Substitution with electron releasing group such as 3, 4, 5- trimethoxy or bulky group like tert-butyl seem to retain the binding ability (-7.08 and -7.521 kJ mol⁻¹) whereas introduction of 4-hydroxyl group decreased the binding affinity (-5.72 kJ mol⁻¹).

Molecular docking studies using COX-2 enzyme:

The COX-2 enzyme (Table.1) consists of three independent folding units: an epidermal growth factor-like domain, a membrane binding site, and an enzymatic domain. NSAIDs bind reversibly with tyrosine 385 amino acid residue and inhibit the enzymatic action and PGE₂ production [33]. Celecoxib, 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide, was used as standard inhibitor for docking studies involving COX-2, which was highly interactive with amino acid residues Leu 338, Arg499, Phe 504 and Arg 106 with the glide score of -11.87 kJ mol⁻¹. Sulfonamide moiety was found to have three hydrogen bonding interactions, two of which involve oxygen atoms present on sulfonyl group

and another is from amino proton. In addition, π - π interactions were found to exist between pyrazole ring of celecoxib and Arg 106 amino acid.

Molecular docking results obtained for COX-2 enzyme, indicate that unsubstituted chalcone (C1) has good affinity for this enzyme, with the interaction energy of -8.644 kJ mol⁻¹. Thus structural features of chalcones are also suitable for interaction with the active site of COX-2 enzyme. Introduction of electron withdrawing groups enhanced the binding affinity of chalcones. Highest binding score was obtained for trifluoromethyl substituted chalcone (C12) that is -9.259 kJ mol⁻¹. Binding modes of chalcones bearing halogens or -CF₃ were similar in the in the binding pocket of COX-2 and were shown to participate in hydrophobic interactions with tyrosine residues situated at 371 and 373 positions in enzyme. With the presence of nitro group at 4th position (C5) improved the binding affinity of the parent molecule (-9.096 kJ mol⁻¹). Nitro group seems to mimic the sulfonyl moiety of celecoxib at the receptor binding site and interacts with Arg 499 and Phe504 amino acid residues.

Presence of hydroxyl group at 4th position of chalcone (C6), binding free energy is increased (-8.970 kJ mol⁻¹) when compared to unsubstituted chalcone (-8.644 kJ mol⁻¹). Replacement of hydroxyl group with methoxy

group led to chalcone with reduced binding affinity for COX-2 (-8.000 mol^{-1}), indicating the importance of hydrogen bonding donor ability of hydroxyl group at this position, which is diminished upon methoxylation. The strong hydrogen bonding ability of the substituent might be playing an important role at the COX-2 binding site.

When 3, 4, 5-trimethoxy groups were introduced, binding affinity of chalcone was retained, whereas introduction of alkyl groups decreased the affinity.

Interpretation of the results of iNOS and COX-2 docking studies reveals that

- i) Electronic effects influence the binding affinities of chalcones. Introduction of trifluoromethyl group was found to be the most favourable at the binding sites of iNOS and COX-2.
- ii) Effect of nitro and hydroxyl groups is opposite. In case of COX-2 enzyme, this group has enhanced the binding affinity whereas for iNOS, presence of this moiety decreased the binding affinity.

Prediction of Molecular and ADME descriptors:

In the chalcones, except for the 4-tert-butyl derivative (C11), all the other derivatives have obeyed the Lipinski rules of five, suggesting that these compounds were predicted to have good oral bioavailability. Predicted ADME descriptors for these chalcones denote that they have good Pharmacokinetic profile (Table.2).

In general, ligands targeted at the CNS tend to have lower PSA (60–70 Å), higher Log BB and BBB values (>0.3 and >0.1). Results of molecular and pharmacokinetic descriptors revealed that most of the chalcones (C1-C4 and C7-C12) have suitable descriptor values for good CNS penetration. These chalcones contain PSA values lesser than 70 Å (17.07–62.90 Å) Log BB values higher than 0.3 (0.34–0.72) and BBB values higher than 0.1 (0.15–8.21) which predict positive CNS permeability. Among all the chalcones, tert-butyl derivative (C11) was predicted to have excellent CNS penetration with optimal PSA, LogBB and BBB descriptor values (17.07, 0.72 and 8.21).

CONCLUSION

Docking studies of a series of ring substituted chalcones revealed that electronic effects play an

important role for binding, with trifluoromethyl group being most favourable for binding. Molecular properties prediction demonstrated that these compounds possess good oral bioavailability and CNS permeability

REFERENCES

1. Begum E. and Rahmiye E. Chemical and Structural Properties of Chalcones I, *Fabad Journal of Pharmaceutical Sciences*, 36: 223-242, (2011)
2. Batovska D. I. and Todorova I. T. Trends in Utilization of the Pharmacological Potential of Chalcones. *Current Clinical Pharmacology*, 5: 1-29, (2010)
3. Lai C.K., Rao Y.K., Chang K.R., Lin C.W., Su H.L., Chang C.S., Lai C.H. and Tzeng Y.M. 3, 3', 4', 5'-Tetramethoxychalcone inhibits human oral cancer cell proliferation and migration via p53-mediated mitochondrial-dependent apoptosis. *Anticancer Research*, 34(4):1811-9, (2014)
4. Achanta G., Modzelewska A. and Feng L. A. Boronic - chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome. *Molecular Pharmacology*, 70: 426-33, (2006)
5. Batovska D., Prushev St. and Slavova A. Study on the substituents effects of a series of synthetic chalcones against the yeast *Candida Albicans*. *European Journal of Medicinal Chemistry*, 42: 87-92, (2007)
6. Yunes R.A., Chiaradia L.D. and Leal P.C., Chalcones as new drugs against leishmaniasis. *Current Trends in Medicinal Chemistry*, 52:47-56, (2006)
7. Hsieh H.K., Tsao L.T. and Wang J.P., Synthesis and antiinflammatory activities of chalcones. *Journal of Pharmacy and Pharmacology*, 52: 163–171, (2000)
8. RamV.J., Saxena A.S. and Srivastava S. Oxygenated chalcones and bischalcones as potential antimalarial agents. *Bioorganic & Medicinal Chemistry Letters*, 10:2159-2161, (2000)
9. Zhao L.M., Jin H.S., and Sun L.P. Synthesis and evaluation of antiplatelet activity of trihydroxy chalcone derivatives, *Bioorganic & Medicinal Chemistry Letters*, 15: 5027-5029, (2005)
10. Satyanarayana M., Tiwari P. and Tripathi B.K. Synthesis and antihyperglycemic activity of chalcone based aryloxypropanolamines. *Bioorganic & Medicinal Chemistry*, 12(5): 883-889, (2004)
11. Shiva kumar P.M., Babu G.S.M. and Mukesh. QSAR studies on chalcones and flavonoids as antitubercular agents using genetic function approximation (GFA) method. *Chemistry & Pharmacy Bulletin*, 55:44-49, (2005)

12. Mallikarjun K. G. Antiviral Activity of Substituted Chalcones and their Respective Cu (ii), Ni (ii) and Zn (ii) Complexes. *E-Journal of Chemistry*, 2 (1): 58-61, (2005)
13. Amita S.R., Lalitha S. and Srinivasan K.K. Synthesis and in vitro antimicrobial evaluation of 5'-acetamido-2'-hydroxy chalcone derivatives. *Research Journal of Chemical Sciences*, 4(2) :56-59, (2014)
14. Elmann A., Telerman A., Erlank H., Mordechay S., Rindner M., Rivka O. and Kashman Y. Protective and Antioxidant Effects of a Chalconoid from *Pulicaria incisa* on Brain Astrocytes. *Oxidative Medicine and Cellular Longevity*, Article ID 694398: (2013)
15. Subhash P., Aamir A., Nikhil O. and Fazlul H S. Emerging role of Garcinol, the antioxidant chalcone from *Garcinia indica* Choisy and its synthetic analogs. *Journal of Hematology and Oncology*, 2: 38, 2009.
16. Bandgara B.P., Gawande S.S. and Badade R.G. Synthesis and biological evaluation of simple methoxylated chalcones as anticancer, antiinflammatory and antioxidant agents. *Bioorganic & Medicinal Chemistry*, 18(3):6-12, (2010)
17. Campos-Buzzi F., Padaratz P., Meria A.V., Correa R., Nunes R.J. and Cachinel-Filho V. 4'-Acetamidochalcone derivatives as Potential Antinociceptive agents, *Molecules*, 12: 896-906, (2007)
18. Correa R., Marcia A.S., Pereira D. B., Lorena d.S., Valdir C.F., Santos R.S. and Nunes J. R. Antinociceptive properties of chalcones-Structure-activity relationships. *Archiv der Pharmazie*, 334(3):32-334, (2001)
19. Campos-Buzzi F., Campos J. P., Patricia P. Y., Rogerio Correa., Yunes R.A., Boeck P. and Cechinel-Filho V. Antinociceptive Effects of Synthetic Chalcones obtained from Xanthoxylone. *Archiv der Pharmazie*, 339(7): 361-365, (2006)
20. Albena T. D., Michael A. M., Richard E. B., Ronald J. H., and Paul T. Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depend on their reactivity with sulfhydryl groups. *PNAS*, 13, 98 (6):3404-3409 (2001)
21. Hannelore R., Nafisah A., Anne R., Eva G., Lidia B., Clarissa G., Tobias P. D. and Sabine A. Enhancing the anti-inflammatory activity of chalcones by tuning the Michael acceptor site. *Organic & Bimolecular Chemistry*, 13: 3040-3047: (2015)
22. K. Sahu, Balbhadra N. S., Choudhary S. and Kohli D. Exploring Pharmacological Significance of Chalcone Scaffold: A Review. *Current Medicinal Chemistry*, 19(2): (17) 209-225, (2012)
23. Lam K.W., Reaz uddin., Liew C. Y., Tham C. L., Israf D. A., Syahida A., Basyaruddin M. A., Zaheer Ul-Haq and Nordin H. L., Synthesis and QSAR analysis of chalcone derivatives as nitric oxide inhibitory agent. *Medicinal Chemistry Research*, 21:1953-1966 (2012)
24. Rao Y. K., Shih-Hua F. and Yew-Min T. Synthesis and Biological evaluation of 3',4',5'-trimethoxychalcone analogues as Inhibitors of nitric oxide production and tumour cell proliferation. *Bioorganic & Medicinal Chemistry*, 17 :7909-7914, (2009)
25. Rojas J, Payá M, Dominguez JN, Luisa Ferrándiz M. The synthesis and effect of fluorinated chalcone derivatives on nitric oxide production *Bioorganic & Medicinal Chemistry Letters*, 5: 12(15): 1951-4, (2002)
26. Mi J. K., Taraman K., Kim D.E., Eung-Seok L., Pil-Hoon P. TI-I-174, a Synthetic Chalcone Derivative, Suppresses Nitric Oxide Production in Murine Macrophages via Heme Oxygenase-1 Induction and Inhibition of AP-1. *Biomolecules and Therapeutics*. 9, 22(5): 390-399 (2014)
27. Rojas, J., Dominguez, J.N., Charris, J. E., Lobo, G., Paya, M., Ferrandiz, M. L.,. Synthesis and inhibitory activity of dimethylamino-chalcone derivatives on the induction of nitric oxide synthase. *Eur. J. Med. Chem.* 37: 699-705 (2002)
28. Rajitha G., Prasad K.V. S. R. G., Umamaheswari A., Pradhan D. and Bharathi K. Synthesis, biological evaluation, and molecular docking studies of N-(a-acetamido cinnamoyl) aryl hydrazone derivatives as antiinflammatory and analgesic agents. *Medicinal Chemistry Research*, 23:5204-5214 (2014)
29. Cianchi F., Perna F. and Masini E. iNOS/COX-2 Pathway Interaction: A Good Molecular Target for Cancer Treatment. *Current Enzyme Inhibition*, 1(2): 97-105, (2015)
30. Sakthivel K. M. and Guruvayoorappan C. *Acacia ferruginea* inhibits inflammation by regulating inflammatory iNOS and COX-2. *Journal of Immunotoxicology*, 13(1): 127-135, (2016)
31. Zhao M.Y., Abraham M.H., Le J., Hersey A., Luscombe C.N., Beck G. and Sherborne B. Rate-limited steps of human oral absorption and QSAR studies. *Pharmaceutical Research*, 19: 1446-1457, (2002)
32. Clark D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. Prediction of blood brain barrier. *Journal of pharmaceutical sciences*, 88:815-821, (1999)
33. Adinarayana K.P.S. and Ashoka Reddy P., Ajay Babu P. Structural Studies on Docking Selective COX-2 Inhibitors *Journal of Bioinformatics & Research*, 1(1): 21-26, (2012)



***Corresponding Author:**

Shaheen begum

Email: shaheen.pharmchem@gmail.com